Long-acting, subcutaneously administered, PYY RA are undergoing early phase clinical trials as obesity treatments either alone or in combination with GLP-1 RA (Table 1, NCT02568306 and NCT03574584). This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.